600079 ST人福
已收盘 07-01 15:00:00
资讯
新帖
简况
ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%
证券之星 · 06-30 17:50
ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%
ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书
智通财经 · 06-25
ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书
ST人福:二级市场波动受多重因素影响
证券之星 · 06-24
ST人福:二级市场波动受多重因素影响
ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设
证券之星 · 06-24
ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设
ST人福:调整定增定价基准日为发行期首日
证券之星 · 06-24
ST人福:调整定增定价基准日为发行期首日
ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作
证券之星 · 06-24
ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作
ST人福:子公司葛店人福已聘请第三方专业机构
证券之星 · 06-24
ST人福:子公司葛店人福已聘请第三方专业机构
ST人福:截至2026年3月31日公司普通股股东总数为80,842户
证券之星 · 06-24
ST人福:截至2026年3月31日公司普通股股东总数为80,842户
ST人福:生产销售化药仿制药
证券之星 · 06-24
ST人福:生产销售化药仿制药
ST人福:公司目前无相关计划
证券之星 · 06-24
ST人福:公司目前无相关计划
ST人福:通过稳定分红、规范股东会议事规则、提升信息披露质量、优化公司治理与内控、多渠道与投资者沟通等方式,切实保护中小投资者合法权益
证券之星 · 06-24
ST人福:通过稳定分红、规范股东会议事规则、提升信息披露质量、优化公司治理与内控、多渠道与投资者沟通等方式,切实保护中小投资者合法权益
ST人福(600079)披露2026年第二次临时股东大会决议公告,XX月XX日股价+3.75%
证券之星 · 06-23
ST人福(600079)披露2026年第二次临时股东大会决议公告,XX月XX日股价+3.75%
异动快报:ST人福(600079)6月23日9点57分触及涨停板
证券之星 · 06-23
异动快报:ST人福(600079)6月23日9点57分触及涨停板
ST人福最新公告:盐酸他喷他多口服溶液获临床试验批准
证券之星 · 06-22
ST人福最新公告:盐酸他喷他多口服溶液获临床试验批准
每周股票复盘:ST人福(600079)拟定增募资30亿至35亿元
证券之星 · 06-20
每周股票复盘:ST人福(600079)拟定增募资30亿至35亿元
ST人福(600079)披露2026年度向特定对象发行A股股票预案(修订稿),6月18日股价下跌1.74%
证券之星 · 06-18
ST人福(600079)披露2026年度向特定对象发行A股股票预案(修订稿),6月18日股价下跌1.74%
人福医药子公司拟以不低于11亿元转让健康产品公司16.3%股权
美股速递 · 06-04
人福医药子公司拟以不低于11亿元转让健康产品公司16.3%股权
ST人福最新公告:拟不低于10.56亿元挂牌转让乐福思16.34%股权
证券之星 · 06-04
ST人福最新公告:拟不低于10.56亿元挂牌转让乐福思16.34%股权
ST人福(600079.SH)子公司注射用盐酸兰地洛尔上市许可申请获受理
智通财经 · 06-03
ST人福(600079.SH)子公司注射用盐酸兰地洛尔上市许可申请获受理
每周股票复盘:ST人福(600079)拟每10股派息4.80元
证券之星 · 05-31
每周股票复盘:ST人福(600079)拟每10股派息4.80元
加载更多
公司概况
公司名称:
人福医药集团股份公司
所属行业:
医药制造业
上市日期:
1997-06-06
主营业务:
人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。
发行价格:
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":16.73,"timestamp":1782889200000,"preClose":16.44,"halted":0,"volume":13065554,"delay":0,"changeRate":0.0176,"floatShares":1543000000,"shares":1632000000,"eps":1.166,"marketStatus":"已收盘","change":0.29,"latestTime":"07-01 15:00:00","open":16.36,"high":16.76,"low":16.3,"amount":216000000,"amplitude":0.028,"askPrice":16.73,"askSize":407,"bidPrice":16.72,"bidSize":1014,"shortable":0,"etf":0,"ttmEps":1.166,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.44,"symbolType":"stock","openAndCloseTimeList":[[1782869400000,1782876600000],[1782882000000,1782889200000]],"highLimit":17.26,"lowLimit":15.62,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.41,"roa":"--","peRate":14.348199,"roe":"3.07%","epsLYR":1.14,"committee":-0.187068,"marketValue":27307000000,"turnoverRate":0.0085,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-02。","floatMarketCap":25817000000},"requestUrl":"/m/hq/s/600079","defaultTab":"news","newsList":[{"id":"2647534581","title":"ST人福(600079)披露将参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会,6月30日股价下跌2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534581","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647534581?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:50","pubTimestamp":1782813036,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,ST人福报收于16.44元,较前一交易日下跌2.14%,最新总市值为268.34亿元。该股当日开盘16.71元,最高16.78元,最低16.4元,成交额达1.91亿元,换手率为0.75%。近日,ST人福发布《关于参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会的公告》。投资者可通过“全景路演”网站、微信公众号“全景财经”或全景路演APP参与。公司高管将在活动中就2025年度业绩、公司治理、发展战略、经营状况等与投资者进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0070","BK0185","BK0188","BK0239","BK0012","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646873824","title":"ST人福(600079.SH)子公司注射用HWS113获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646873824","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646873824?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:25","pubTimestamp":1782375912,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的注射用HWS113的《药物临床试验批准通知书》。据悉,注射用HWS113是一款治疗用生物制品1类新药,拟用于慢性瘙痒的治疗。慢性瘙痒定义为瘙痒持续超过6周,其严重影响患者的生活质量,导致睡眠障碍、影响社交与工作,引起焦虑或抑郁等负面心理问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0012","BK0096","BK0185","600079","BK0239","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893090","title":"ST人福:二级市场波动受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893090?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:30","pubTimestamp":1782289834,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:每天起床就扣钱,还有救吗,尊敬的邓总ST人福回复:尊敬的投资者,您好!二级市场波动受宏观经济、行业政策、市场情绪及公司基本面等多重因素影响,敬请理性看待。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600079","BK0185","BK0028","BK0096","BK0070","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645389301","title":"ST人福:公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2645389301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645389301?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:27","pubTimestamp":1782289632,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:战投部卢硕说贵司不缺的就是招商有资金,股价低迷何不进行回购注销这样岂不是达到招商提高股份占比的想法ST人福回复:尊敬的投资者,您好!股份回购的实施主体为上市公司而非控股股东。公司拟通过本次发行向控股股东募集资金用于研发创新、产能升级和数智化建设,旨在夯实核心主业竞争力、优化资本结构。公司将深耕核心医药业务,通过持续夯实经营基本面维护股东长期利益,感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0096","BK0185","BK0028","BK0070","600079","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893057","title":"ST人福:调整定增定价基准日为发行期首日","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893057?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:27","pubTimestamp":1782289631,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福06月24日在投资者关系平台上答复投资者关心的问题。公司已于2026年6月18日召开董事会审议通过了调整定增定价基准日为发行期首日,保障定价公允,切实维护中小投资者利益。子公司葛店人福已聘请第三方专业机构推进厂区整改,并持续与FDA保持沟通,将尽快完成鄂州厂区整改、解除警示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0185","600079","BK0028","BK0239","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645932928","title":"ST人福:公司将在股东会审议通过之日起2个月内完成本次分红实施工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645932928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645932928?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289484,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司上周五己召开股东大会通过2025年利润分配提案,什么时候可以实施分红ST人福回复:尊敬的投资者,您好!公司2025年年度利润分配方案已于2026年6月5日经2025年年度股东会审议通过,公司将在股东会审议通过之日起2个月内完成本次分红实施工作。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0188","BK0096","BK0070","600079","BK0185","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645932678","title":"ST人福:子公司葛店人福已聘请第三方专业机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2645932678","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645932678?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289482,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:想问下关于FDA对葛店人福的警告信情况,是否引入第三方专业顾问是否需要提交延期申请,违规问题整改情况ST人福回复:尊敬的投资者,您好!子公司葛店人福已聘请第三方专业机构,并持续与FDA保持沟通,将尽快完成鄂州厂区整改、解除警示。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0070","BK0239","BK0012","BK0096","BK0185","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893298","title":"ST人福:截至2026年3月31日公司普通股股东总数为80,842户","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893298?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289482,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2026年5月31日,公司股东人数多少?ST人福回复:尊敬的投资者,您好!根据上市公司信息披露相关规定以及信息披露原则,公司会在定期报告中披露对应时点的股东户数及前十名股东情况,敬请查阅公司在上海证券交易所网站上刊登的定期报告。公司最近一次披露的股东户数是截至2026年3月31日的公司普通股股东总数,为80,842户。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0028","BK0070","BK0188","BK0096","BK0012","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893262","title":"ST人福:生产销售化药仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893262?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:24","pubTimestamp":1782289481,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:公司在非洲的子公司生产经营的产品是什么?产品销售受限制吗?业务发展预期趋势怎么样?经营的效益好不好?ST人福回复:尊敬的投资者,您好!公司已在非洲马里、埃塞俄比亚建成现代化制药工厂,生产销售的产品为化药仿制药,主要满足当地及周边区域民众基础用药需求。公司积极克服当地政局动荡、能源短缺等困难,践行企业责任,保持稳定发展。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400029459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0070","BK0188","BK0185","BK0096","BK0028","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893674","title":"ST人福:公司目前无相关计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893674?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:09","pubTimestamp":1782288568,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:新疆维药有没单独IPO的计划ST人福回复:尊敬的投资者,您好!公司目前无相关计划。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400027625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","600079","BK0188","BK0239","BK0012","BK0096","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645605893","title":"ST人福:通过稳定分红、规范股东会议事规则、提升信息披露质量、优化公司治理与内控、多渠道与投资者沟通等方式,切实保护中小投资者合法权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2645605893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645605893?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:09","pubTimestamp":1782288560,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:招商在保护中小投资者者合法权益方面,做过哪些?ST人福回复:尊敬的投资者,您好!公司通过稳定分红、规范股东会议事规则、提升信息披露质量、优化公司治理与内控、多渠道与投资者沟通等方式,切实保护中小投资者合法权益。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400027607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0070","BK0239","BK0012","BK0096","BK0185","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645583405","title":"ST人福(600079)披露2026年第二次临时股东大会决议公告,XX月XX日股价+3.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645583405","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645583405?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:07","pubTimestamp":1782223623,"startTime":"0","endTime":"0","summary":"根据ST人福2026年6月23日收盘行情及最新公告信息:截至2026年6月23日收盘,ST人福报收于17.16元,较前一交易日上涨3.75%,最新总市值为280.09亿元。近日,ST人福发布《2026年第二次临时股东会决议公告》。公告显示,公司于2026年6月23日召开2026年第二次临时股东会,会议由董事常黎主持,采用现场与网络投票相结合方式召开,出席会议的股东及代理人共1,453人,代表有表决权股份总数的43.064%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","600079","BK0188","BK0239","BK0012","BK0096","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645012670","title":"异动快报:ST人福(600079)6月23日9点57分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2645012670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645012670?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:06","pubTimestamp":1782180366,"startTime":"0","endTime":"0","summary":"证券之星6月23日盘中消息,9点57分ST人福(600079)触及涨停板。其所属行业化学制药目前上涨。领涨股为亨迪药业。该股为肝炎概念,化学原料药,创新药概念热股,当日肝炎概念概念上涨4.28%,化学原料药概念上涨3.89%,创新药概念上涨3.71%。6月22日的资金流向数据方面,主力资金净流出59.79万元,占总成交额0.26%,游资资金净流入18.99万元,占总成交额0.08%,散户资金净流入40.79万元,占总成交额0.18%。近5日资金流向一览见下表:ST人福主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300010952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0185","BK0239","BK0070","BK0188","600079","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023651","title":"ST人福最新公告:盐酸他喷他多口服溶液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023651","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023651?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:36","pubTimestamp":1782121017,"startTime":"0","endTime":"0","summary":"ST人福(600079.SH)公告称,控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的盐酸他喷他多口服溶液《药物临床试验批准通知书》。盐酸他喷他多口服溶液临床上拟用于缓解体重超过16公斤的2岁以上儿童和成人的中度至重度急性疼痛,这些疼痛仅可使用阿片类镇痛药才能充分控制。目前盐酸他喷他多口服溶液尚未在国内上市。截至目前,宜昌人福在该项目上的累计研发投入约370万元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0028","BK0070","BK0012","BK0188","BK0185","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063823","title":"每周股票复盘:ST人福(600079)拟定增募资30亿至35亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063823","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063823?lang=zh_cn&edition=full","pubTime":"2026-06-20 01:47","pubTimestamp":1781891231,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,ST人福报收于16.41元,较上周的17.32元下跌5.25%。本周,ST人福6月15日盘中最高价报17.49元。ST人福当前最新总市值267.85亿元,在化学制药板块市值排名12/150,在两市A股市值排名813/5206。本周关注点来自公司公告汇总:ST人福拟定增募资不低于300,000万元且不超过350,000万元,用于创新药研发及补充流动资金等项目。发行数量不超过234,113,712股,且不超过发行前总股本的30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0185","BK0012","BK0188","BK0096","BK0239","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644081248","title":"ST人福(600079)披露2026年度向特定对象发行A股股票预案(修订稿),6月18日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644081248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644081248?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:16","pubTimestamp":1781792178,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,ST人福报收于16.41元,较前一交易日下跌1.74%,最新总市值为267.85亿元。近日,ST人福披露《2026年度向特定对象发行A股股票预案(修订稿)》。公告显示,公司拟向特定对象发行A股股票,募集资金总额不低于30亿元且不超过35亿元,发行对象为其控股股东招商生命科技(武汉)有限公司,构成关联交易。发行完成后,控股股东认购的股份自发行结束之日起36个月内不得转让。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800042421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159982","BK0028","BK0096","BK0070","399300","BK0012","600079","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168472478","title":"人福医药子公司拟以不低于11亿元转让健康产品公司16.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1168472478","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168472478?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:01","pubTimestamp":1780567316,"startTime":"0","endTime":"0","summary":"人福医药集团宣布,其子公司Rfsw计划转让一家健康产品公司16.3%的股权,转让价格将不低于11亿元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0188","BK0185","600079","BK0028","BK0239","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159331","title":"ST人福最新公告:拟不低于10.56亿元挂牌转让乐福思16.34%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640159331?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:00","pubTimestamp":1780567245,"startTime":"0","endTime":"0","summary":"ST人福(600079.SH)公告称,公司全资子公司RFSWHoldingPte.Ltd.拟在产权交易所公开挂牌转让乐福思健康产业股份公司16.34%股权,挂牌转让价格拟不低于评估值10.56亿元。本次交易不影响公司合并报表范围,交易完成后公司不再持有乐福思股权。若按评估值测算,预计影响当期损益约5亿元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400031805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0096","BK0070","BK0012","600079","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640974253","title":"ST人福(600079.SH)子公司注射用盐酸兰地洛尔上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640974253","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640974253?lang=zh_cn&edition=full","pubTime":"2026-06-03 15:51","pubTimestamp":1780473095,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的注射用盐酸兰地洛尔的药品注册上市许可申请《受理通知书》。注射用盐酸兰地洛尔为选择性β1受体阻断剂,临床适用于:1、手术过程中发生的下列快速性心律失常的紧急治疗:心房纤颤、心房扑动、窦性心动过速;2、手术后循环系统动态监护时发生的快速性心律失常的紧急治疗:心房纤颤、心房扑动、窦性心动过速;3、心功能不全患者发生下列快速性心律失常的治疗:心房纤颤、心房扑动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0012","BK0096","BK0188","BK0028","BK0070","600079","BK0185","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639067601","title":"每周股票复盘:ST人福(600079)拟每10股派息4.80元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639067601","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639067601?lang=zh_cn&edition=full","pubTime":"2026-05-31 02:30","pubTimestamp":1780165830,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,ST人福报收于17.5元,较上周的17.88元下跌2.13%。本周,ST人福5月25日盘中最高价报17.94元。ST人福当前最新总市值285.64亿元,在化学制药板块市值排名13/150,在两市A股市值排名745/5207。本周关注点来自公司公告汇总:ST人福拟每10股派发现金红利4.80元(含税)公司公告汇总人福医药集团股份公司2025年年度股东会会议资料包括会议议程、董事会工作报告、财务决算与预算报告、利润分配方案等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0096","BK0185","BK0028","BK0070","BK0239","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782901121723,"stockEarnings":[{"period":"1week","weight":-0.042},{"period":"1month","weight":-0.0606},{"period":"3month","weight":-0.1379},{"period":"6month","weight":-0.0922},{"period":"1year","weight":-0.2043},{"period":"ytd","weight":-0.0922}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.0316},{"period":"1year","weight":0.1887},{"period":"ytd","weight":0.0316}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"80842人(较上一季度减少3.87%)","perCapita":"19088股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。经过30多年的发展,公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}